Skip to main content
Log in

Nelfinavir associated with peripheral neuropathy in an HIV-infected patient

  • Correspondence
  • Published:
Infection Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Patick, A. K., Boritzki, T. J., Bloom, L. A.: Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfnavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infectionin vitro. Antimicrob. Agents Chemother. 41 (1996) 2159–2164.

    Google Scholar 

  2. Peterson, A. K., Gersten, M., Knowles, M., Chang, Y., Yu, G., Clendeninn, N. J. (Agouron Pharmaceuticals, La Jolla, CA) for the Viracept Cooperative Study Group: Long-term virological and immunological response to treatment with viracept (nelfinavir mesylate) in combination with zidovudine and lamivudine. Program and abstracts of the Sixth European Conference on Clinical Aspects of HIV-Infection, Hamburg, Germany 1997, abstr. no. 210.

  3. Nelfinavir prescribing information. Agouron Pharmaceuticals Inc., La Jolla, CA, USA.

  4. McDonald, C. K., Kuritzkes, D. R.: Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157 (1997) 951–959.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grunke, M., Kraetsch, H.G., Löw, P. et al. Nelfinavir associated with peripheral neuropathy in an HIV-infected patient. Infection 26, 252 (1998). https://doi.org/10.1007/BF02962377

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02962377

Keywords

Navigation